10.1007/s10147-023-02390-2 - First-line nivolumab plus ipilimumab ...

This document has been corrected

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

10.1007/s10147-023-02390-2

Published Online: 2023-08-07

Journal: International Journal of Clinical Oncology•Publisher: Springer Science and Business Media LLC

Authors: Haruko Daga•Hideaki Mizutani•Hidetoshi Hayashi•Hiroshi Tanaka•Isamu Okamoto•Judith Bushong•Katsuyuki Hotta•Kazuo Kasahara•Li Li•Makoto Nishio•Ravi G. Gupta•Satoshi Ikeda•Shunichi Sugawara•Tateaki Naito•Tatsuro Fukuhara•Toshihide Yokoyama•Yuichiro Ohe•Yuki Sato

This document has been corrected

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

10.1007/s10147-023-02390-2

Published Online: 2023-08-07

Journal: International Journal of Clinical Oncology

NOW

2023-09-09•Correction

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

10.1007/s10147-023-02408-9

* information provided by CrossRef

2023-09-09•Correction

10.1007/s10147-023-02408-9

* information provided by CrossRef

2023-08-07•Published

2023-09-09•Correction

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

10.1007/s10147-023-02408-9

* information provided by CrossRef

This document has been corrected

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

10.1007/s10147-023-02390-2

Published Online: 2023-08-07

Journal: International Journal of Clinical Oncology•Publisher: Springer Science and Business Media LLC